CLL1-CD33-NKG2D CAR-T for relapsed/refractory AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of immune cell therapy (CAR-T) that targets three proteins (CLL1, CD33, NKG2D) on leukemia cells in patients with acute myeloid leukemia that has not responded to or come back after prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have acute myeloid leukemia that has returned or not responded to at least one prior treatment.
- You must be well enough to undergo apheresis (a blood collection procedure) to get cells for the therapy.
- Your kidneys, liver, and blood counts must be within certain limits.
- You cannot have active leukemia in the brain or spinal cord, or have other serious uncontrolled illnesses.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a two-step treatment: first a targeted immune cell therapy (CLL1 CAR-T) to attack leukemia cells, followed by a stem cell transplant to rebuild healthy blood cells. It is for people with acute myeloid leukemia that has returned or not responded to previous chemotherapy.
This trial tests a combination of CAR-T cell therapies (targeting CD123, CLL-1, and CD7) followed by a stem cell transplant for people with acute myeloid leukemia that has returned or not improved. The goal is to see if this approach can help eliminate the leukemia and prepare for a transplant.
This trial tests a new type of immune cell therapy (CAR-T) designed to find and kill leukemia cells that carry two specific markers (CLL-1 and CD33). It is for adults with acute myeloid leukemia that has come back or is not responding to standard treatments.
This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.
This trial tests a lab-made immune cell treatment (CAR-T) made to target AML cells with a specific marker (NKG2D ligand). It’s for people whose acute myeloid leukemia (AML) has come back or didn’t respond to standard chemotherapy.
This trial tests a therapy made from your own immune cells, engineered to target a marker called CLL-1 on leukemia cells, for people whose AML has come back or hasn't responded to standard treatments.
Hear when a new AML (Acute Myeloid Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.